Shares of Cresco Labs Inc. (OTCMKTS:CRLBF - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $2.50.
A number of research firms have weighed in on CRLBF. Cormark downgraded Cresco Labs from a "moderate buy" rating to a "hold" rating in a report on Monday, November 11th. Roth Capital upgraded Cresco Labs to a "strong-buy" rating in a report on Sunday, November 10th. Finally, Atb Cap Markets downgraded Cresco Labs from a "strong-buy" rating to a "hold" rating in a report on Monday, December 9th.
Read Our Latest Stock Analysis on CRLBF
Cresco Labs Stock Up 0.2 %
Shares of CRLBF stock traded up $0.00 during midday trading on Wednesday, reaching $0.88. 330,589 shares of the stock were exchanged, compared to its average volume of 530,689. Cresco Labs has a 1 year low of $0.78 and a 1 year high of $2.60. The company's 50 day moving average is $0.91 and its two-hundred day moving average is $1.28. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80. The firm has a market cap of $430.30 million, a PE ratio of -4.41 and a beta of 1.79.
About Cresco Labs
(
Get Free ReportCresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Further Reading
Before you consider Cresco Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.
While Cresco Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
